Natera reports preliminary Q4 revenue $660M, consensus $577.62M

Reports preliminary FY25 revenue $2.3B, consensus $2.22B. Approximately 923,600 tests were processed in the fourth quarter compared to 792,800 tests in the fourth quarter of 2024, an increase of 17%. Approximately 3,525,500 tests were processed in FY25 compared to 3,064,600 tests in the full year 2024, an increase of approximately 15%. “2025 was a record year for oncology, organ health and women’s health,” said Steve Chapman, CEO of Natera (NTRA). “The fourth quarter was particularly strong, with excellent growth in volume, revenue and gross margins. We believe we are well positioned to continue building on this momentum in 2026 and beyond.”